GSK Gets Canadian Approval for BREO ELLIPTA for Treatment of Asthma in Adults – RTT News

GSK Gets Canadian Approval for BREO ELLIPTA for Treatment of Asthma in Adults
RTT News
GlaxoSmithKline plc (GSK) and Theravance, Inc. (THRX) on Thursday announced the approval in Canada of BREO ELLIPTA for the once-daily maintenance treatment of asthma in patients aged 18 years and older with reversible obstructive airways disease.
GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment of Adults With MarketWatch

all 4 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.